Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Innovent Starts China Trial of PI3Kδ Inhibitor for Indolent Lymphoma

publication date: Apr 28, 2020

Suzhou Innovent Bio, has dosed the first patient in a pivotal China Phase II registrational trial of parsaclisib, a novel and selective PI3Kδ inhibitor. The trial is aimed at testing the efficacy and safety of parsaclisib in patients with indolent lymphoma -- either recurrent/refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL). In 2018, Innovent acquired greater China rights from Incyte for three clinical-stage candidates, including parsaclisib. Incyte is already testing parsaclisib in several non-Hodgkin lymphomas and in myelofibrosis, diffuse large B-cell lymphoma and autoimmune hemolytic anemia. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here